Figure 1
Flow chart for the global scoping review of dyslipidaemia management guidance.
Table 1
Past non-WHO dyslipidaemia guidelines considered in this scoping review.
| GEOGRAPHY | PUBLICATION YEAR | TITLE | INCLUSION STATUS/REASON FOR EXCLUSION | CITATIONS |
|---|---|---|---|---|
| Regional dyslipidaemia management guidelines | ||||
| Asia Pacific | 2021 | Asia Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia | Exclude. Reasons: management recommendations focused on CVD patients and other very high-risk groups, few primary prevention recommendations; authors report multiple potential conflicts of interest. | Koh (26) |
| Europe | 2025 | 2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias | Include | Mach (27) |
| Europe | 2021 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice | Include | Visseren (28) |
| Europe | 2019 | European Society of Cardiology/European Atherosclerosis Society Lipid Guidelines | Include | Mach (27) |
| National dyslipidaemia management guidelines | ||||
| China | 2023 | Chinese Guideline for Lipid Management | Include | Li (29) |
| India | 2023 | Lipid Association of India Dyslipidemia Guidelines | Exclude. Reasons: emphasis on diagnostic testing not available at primary care or local hospital levels; authors report multiple potential conflicts of interest. | Puri (30) |
| Sri Lanka | 2021 | Sri Lankan Ministry of Health Dyslipidaemia Management Guidelines | Include | Ministry of Health (31) |
| Brazil | 2020 | Brazil Ministry of Health Dyslipidaemia Management Guidelines | Include | Ministry of Health (6) |
| Kenya | 2018 | Kenya National Guidelines for Cardiovascular Diseases Management | Include | Ministry of Health (6) |
| USA | 2018 | AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Include | Grundy (32) |
| Egypt | 2017 | Egyptian Consensus of Dyslipidaemia Management | Include | Ministry of Health (6) |
| Mexico | 2016 | Mexican Dyslipidaemia Management Guidelines | Include | Mexican Institute for Social Security (6) |
Table 2
Evidence mapping to dyslipidaemia management guideline priority topics: results of structured MEDLINE search.
| GUIDELINE PRIORITY TOPIC | GUIDELINE SUBTOPIC | META-ANALYSES OF RCTS WITH CVD OUTCOMES IDENTIFIED IN STRUCTURED SEARCH | OTHER REVIEWS OR SINGLE TRIAL REPORTS |
|---|---|---|---|
| Lipid-lowering treatment eligibility | Secondary prevention | Pignone (33) CTT 2005 (34) | |
| Primary prevention: high risk defined by single risk factor | Major (CKD) (36) Gami (diabetes) (37) Ponce (elderly) (35) | Hou (CKD) (38) Palmer(CKD) (39) Upadhyay (CKD) (40) Navaneethan (CKD) (41) Grinspoon (HIV) (42) De Vries (diabetes) (43) CTT 2008 (diabetes) (44) CTT 2019 (elderly) (45) Gencer (elderly) (46) | |
| Primary prevention: other risk groups | CTT 2012 (low CVD risk) (47) Karmali (CVD risk scores) (48) Pignone (all primary) (33) | ||
| Lipid-lowering treatment choice | Statin therapy intensity | Hsu (49) Josan (50) Chan (51) Blasetto (52) | Smilde (FH) (53) |
| Non-statin therapies (alone or combined with statin) | Hsu (49) Koskinas (54) Hosseni (55) Wu (56) Wang (57) Sayed (58) Sydhom (59) Navarese (60) Savarese (61) Du (62) Imran (63) Schmidt (64) Toth (65) | Perez de Isla (FH) (66) | |
| Lipid-lowering treatment goal | Shepherd (67) | Jones (68) Rosenson (69) | |
| Lipid-lowering treatment monitoring and follow-up for efficacy or harms | None | CTT 2019 (45) Chou (20) Collins (21) CTT 2010 (18) | |
| Equity | Gender stratified analysis | CTT 2015 (19) |
[i] Abbreviations:
CTT: Cholesterol Lowering Trialists
CKD: Chronic Kidney Disease
CVD: Cardiovascular Disease
FH: Familial Hypercholesterolemia
HIV: Human Immunodeficiency Virus